Introduction: To investigate the ability of cardiovascular plasma biomarkers to identify imminent preeclampsia (PE) among pregnant women at triage. Material and Methods: C-terminal pro-arginine vasopressin (copeptin), C-terminal pro-endothelin-1 (CT-proET-1), mid-regional pro-adrenomedullin (MR-proADM), and mid-regional pro-atrial natriuretic peptide (MR-proANP) were prospectively measured in pregnant women presenting at the obstetrical triage units of the University Hospitals of Basel and Zurich, Switzerland. Logistic regression and receiver operating characteristics (ROC) analysis was used to assess and quantify the predictive ability of cardiovascular biomarkers. Results: Of the 147 included women, 27 (18.4%) were diagnosed at admission with PE. All biomarker levels were significantly higher in participants with PE as compared to controls. However, only MR-proANP, MR-proADM and CT-proET-1 were significant and independent predictors of PE, after taking into account the effect of various clinical confounders. The area under the ROC curve (AUC) was 0.62 (95% confidence interval 0.50-0.73) for copeptin, 0.64 (0.52-0.76) for MR-proADM, 0.71 (0.61-0.82) for CT-proET-1, and 0.83 (0.73-0.92) for MR-proANP. The combination of MR-proANP and MR-proADM resulted in the highest diagnostic performance (AUC 0.88; 0.79-0.96). Discussion: Assessment of the cardiovascular plasma biomarkers MR-proANP and MR-proADM holds promise to support diagnosis of PE at triage.

Keywords:
Biomarker, Preeclampsia, At triage, Vasoactive peptides, Pregnancy, Obstetrics, Cardiovascular
1.
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H: Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011;32(suppl):S4-S16.
2.
Redman CW, Sargent IL: Latest Advances in Understanding Preeclampsia. Science 2005;308:1592-1594.
3.
Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS: Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187-1207.
4.
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H: The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58.e51-e58.
5.
Mosimann B, Wagner M, Poon LC, Bansal AS, Nicolaides KH: Maternal serum cytokines at 30-33 weeks in the prediction of preeclampsia. Prenat Diagn 2013;33:823-830.
6.
Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, Harper A, Hulbert D, Lucas S, McClure J, Millward-Sadler H, Neilson J, Nelson-Piercy C, Norman J, O'Herlihy C, Oates M, Shakespeare J, de Swiet M, Williamson C, Beale V, Knight M, Lennox C, Miller A, Parmar D, Rogers J, Springett A: Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118(suppl 1):1-203.
7.
Shennan AH, Redman C, Cooper C, Milne F: Are most maternal deaths from pre-eclampsia avoidable? Lancet 2012;379:1686-1687.
8.
Sibai BM: Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol 2011;205:191-198.
9.
Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS: Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006;113:369-378.
10.
Nickel CH, Bingisser R, Morgenthaler NG: The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 2012;10:7.
11.
Benzing J, Stabile O, Szinnai G, Morgenthaler NG, Schulzke SM, Buhrer C, Wellmann S: Plasma pro-endothelin-1 and respiratory distress in newborn infants. J Pediatr 2012;160:517-519.
12.
Khaleghi M, Al-Omari MA, Kondragunta V, Morgenthaler NG, Struck J, Bergmann A, Mosley TH, Kullo IJ: Relation of plasma midregional proatrial natriuretic peptide to target organ damage in adults with systemic hypertension. Am J Cardiol 2009;103:1255-1260.
13.
Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S, Holzgreve W, Hahn S, Lapaire O: Potential markers of preeclampsia - a review. Reprod Biol Endocrinol 2009;7:70.
14.
Admaty D, Benzing J, Burkhardt T, Lapaire O, Hegi L, Szinnai G, Morgenthaler NG, Ulrich Bucher H, Buhrer C, Wellmann S: Plasma midregional proadrenomedullin (mr-proadm) in newborn infants: Impact of prematurity and perinatal infection. Pediatr Res 2012;72:70-76.
15.
Burkhardt T, Schwabe S, Morgenthaler NG, Natalucci G, Zimmermann R, Wellmann S: Copeptin: A marker for stress reaction in fetuses with intrauterine growth restriction. Am J Obstet Gynecol 2012;207:497.e1-e5.
16.
Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H: An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1-161.
17.
Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA: Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911-919.
18.
Sugulle M, Herse F, Hering L, Mockel M, Dechend R, Staff AC: Cardiovascular biomarker midregional proatrial natriuretic peptide during and after preeclamptic pregnancies. Hypertension 2012;59:395-401.
19.
Khaleghi M, Saleem U, Morgenthaler NG, Turner ST, Bergmann A, Struck J, Mosley TH, Kullo IJ: Plasma midregional pro-atrial natriuretic peptide is associated with blood pressure indices and hypertension severity in adults with hypertension. Am J Hypertens 2009;22:425-431.
20.
Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, Danisman N: Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res 2011;37:1198-1202.
21.
Shmueli A, Meiri H, Gonen R: Economic assessment of screening for pre-eclampsia. Prenat Diagn 2012;32:29-38.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.